Form 4: Natera Executive Sells Shares Under 10b5-1 Plan

Natera's President of Clinical Diagnostics, Solomon Moshkevich, sold 2,951 shares of common stock for approximately $675,800 under a pre-arranged 10b5-1 trading plan.

Summary

• Solomon Moshkevich, President, Clinical Diagnostics of Natera, Inc. (NTRA), sold a total of 2,951 shares of common stock.
• The sales occurred on January 2, 2026.
• 1,292 shares were sold at a weighted average price of $228.3294 per share, with prices ranging from $227.8050 to $228.76.
• 1,659 shares were sold at a weighted average price of $229.4273 per share, with prices ranging from $228.94 to $229.73.
• The estimated total proceeds from these sales are approximately $675,800.
• The transactions were executed pursuant to a Rule 10b5-1 trading plan adopted on November 26, 2024.
• Following these transactions, Moshkevich beneficially owns 123,499 shares of Natera common stock.

Sentiment

Score: 5

Explanation: The sentiment is neutral. While insider selling can be viewed negatively, the execution under a pre-arranged 10b5-1 plan mitigates concerns, suggesting personal financial planning rather than a lack of confidence in the company's immediate prospects. It's a routine disclosure for an insider transaction.

Positives

• The sale was conducted under a Rule 10b5-1 trading plan, indicating a pre-scheduled transaction rather than a reaction to recent company news, which can mitigate negative interpretations of insider selling.

Negatives

• An insider, the President of Clinical Diagnostics, sold a significant number of shares (2,951 shares) of company stock.
• Insider selling, even under a 10b5-1 plan, can sometimes be perceived as a lack of confidence in the company's future stock price performance, although this is often for personal financial planning.

Future Outlook

NA

Industry Context

This filing is a routine insider transaction and does not inherently provide specific industry context. Insider sales are common for personal financial planning, especially under 10b5-1 plans, and do not necessarily reflect on the broader industry trends of clinical diagnostics or Natera's competitive position.

Related Party Transactions

• Solomon Moshkevich, President, Clinical Diagnostics, sold 2,951 shares of Natera common stock.

Stakeholder Impact

• Shareholders: May interpret the insider sale differently; some might see it as a negative signal, while others will recognize it as a routine 10b5-1 transaction for personal liquidity.

Key Dates

Recommendation

This Form 4 filing reports a routine insider sale executed under a pre-established 10b5-1 trading plan. Such transactions are typically for personal financial management and do not usually signal a change in the company's fundamental outlook or warrant a change in investment recommendation. Therefore, a 'hold' recommendation is appropriate as this specific filing does not provide new information to alter an existing investment thesis.

Keywords

Natera, NTRA, Insider Trading, Form 4, Solomon Moshkevich, Stock Sale, 10b5-1 Plan, Clinical Diagnostics, Beneficial Ownership